Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab-Reference-Cited by-同舟云学术

Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab

Published:2018-04-13 Issue:7 Volume:17 Page:1454-1463
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Kurdi Ahmed T.,Glavey Siobhan V.,Bezman Natalie A.,Jhatakia Amy,Guerriero Jennifer L.,Manier Salomon,Moschetta Michele,Mishima Yuji,Roccaro Aldo,Detappe Alexandre^ORCID,Liu Chia-Jen,Sacco Antonio,Huynh Daisy,Tai Yu-Tzu,Robbins Michael D.,Azzi Jamil,Ghobrial Irene M.

Funder

HHS | NIH | National Cancer Institute (NCI)

Leukemia and Lymphoma Society (LLS)

Bristol-Myers Squibb (BMS)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modulating macrophage-mediated programmed cell removal: An attractive strategy for cancer therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. “Find Me” and “Eat Me” signals: tools to drive phagocytic processes for modulating antitumor immunity;Cancer Communications;2024-06-23

3. Therapeutic progress in relapsed/refractory multiple myeloma;Annals of Hematology;2024-04-13

4. Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model;Blood Advances;2024-04-11

5. Daratumumab‑resistant multiple myeloma with extramedullary disease successfully treated with combination elotuzumab, pomalidomide and dexamethasone: A case report;Oncology Letters;2024-04-03